Biomaterials developer Auxilium Health has announced a rebrand and change of name to Aeris Biosciences.
The name Aeris is designed to reflect what the company's biomaterials are at their core. "Aer" signals their foundation, their lightness, and spatial openness, while "Biosciences" anchors the company in scientific rigor and clinical impact. Together they name a company built to work the way biology works: in three dimensions, where the architecture and surface of a material becomes the framework the body builds on, Aeris Biosciences said.
Aeris Biosciences is developing a new class of bioaerogels that reduce the risk of bacterial colonization and guide tissue regeneration. Its Aer platform spans wound repair, bone regeneration, and localized therapeutic delivery, with a lead product advancing toward FDA clearance and clinical studies.
RTW Biotech portfolio company Yarrow Bioscience completes merger
Lupin's Diazepam Injection, USP receives US approval
Auxilium Health changes name to Aeris Biosciences
Saol Therapeutics' SL1009 (DCA) resubmission accepted by FDA
Lantern Pharma advances EMA-cleared Phase 1b/2 bladder cancer trial for LP-184
AcuCort secures renewed FDA fee waiver ahead of planned NDA submission
Yarrow Bioscience completes VYNE merger and begins Phase 2 trial of YB-101